Plantago lanceolata it the most important natural remedy of all to heal eczema and dermatitis. Plantago lanceolata leaves had been adopted as a natural medicine since prehistoric times and is especially well known for it's anti-itch properties. It provides immediate relief to dermatitis, eczema and other skin conditions because of its strong ability to draw out toxins and soothe and reduce inflammation naturally.
Altheys Laboratory highlights the fact that plantago lanceolata components cause the neutralization of nitric oxide, the mediator responsible for vasodilation and therefore inflammation of the skin. Plantago lanceolata prevents vessel dilation by capturing and destroying nitric oxide. By capturing and destroying nitric oxide, plantago lanceolat helps fight itching and redness and above all has no toxicity.
Because of its anti-inflammatory properties the extract of plantago lanceolata reduces immediately irritation and inflammation. It has astringent and antioxidant properties and supports the skin's natural healing processes.

All our skin cosmetics are formulated from plantago lanceolata extract that we cultivate in our domain in the south of France, in Lozere, the little village of Albaret le Comtal (French patent - N° 15 704 040 3 1109 )

To date plantago lanceolata extract is the most powerful weed to heal eczema and dermatitis naturally and without cortisone. The benefits of plantago lanceolata on eczema and dermatitis are just miraculous.

One of our last custumer review:

"Tremendous ! The eczema products work really well and are pleasant to use. After 15 years of corticosteroids, no longer needed... No other dermatological product had worked like this. Fast delivery, good customer service, the responsiveness and friendliness of which I had the opportunity to appreciate" Mireille T.

 

plantain ALTHEYS Zematopic® eczema therapy body cream is the most efficient solution in the world to fight eczema, psoriasis and dermatitis.

Altheys is the first company in the world to isolate and patent the active molecules of Plantago Lanceolata.

We has filed patent applications in Europe in 2015 on the use of o-quinone extracted from Plantago Lanceolata for the treatment of atopic dermatitis and other medical conditions (including arthritis, psoriasis, bronchitis, sepsis, etc.).

plantain Atopic Dermatitis is a common inflammatory skin disease

• Atopic Dermatitis is a common chronic skin disease affecting 10-20% of the general population

• It is characterized by pruritus, eczematous lesions, generalized skin dryness and inflammation.

• Skin barrier dysfunction and low level chronic inflammation are both considered hallmarks of atopic dermatitis

• Most patients (~80%) have a mild to moderate form of disease

• Established treatments for mild to moderate atopic dermatitis include:

– Emollients

– Topical corticosteroids

– Topical calcineurin inhibitors

– Topical PDE4 inhibitor (recently approved)

• A survey of dermatologists indicates that more treatment options are needed for the mild to moderate patient segment

plantain Nitric oxide is an important biological mediator

• Nitric Oxide (NO) is a gaseous free radical which is an important biological mediator in nearly every organ system

• NO is generated in biologic tissues by nitric oxide synthases (eNOS, nNOS, and iNOS)

• NO plays a key role in innate immunity and inflammation – Acts as a toxic defense molecule against infectious organisms – Regulates the functional activity, growth and death of many immune and inflammatory cell types including macrophages, T lymphocytes, antigen-presenting cells, mast cells, neutrophils and natural killer cells

• NO has been found in several skin cell types, including keratinocytes, melanocytes, Langerhans cells, fibroblasts, and endothelial cells

• Increased nitric oxide production is demonstrated in psoriasis, atopic dermatitis, irritant dermatitis, allergic dermatitis, lupus erythematous, sunburn-induced flushing, nerve-mediated flushing and skin swelling

plantainNitric oxide production is increased in atopic skin

plantainIncreased nitric oxide in the skin leads to local inflammation

• NO acts upstream of the inflammatory process, initiating a cascade of signaling events

• Increases in nitric oxide in the skin lead to:

– Vasodilation through cGMP-dependent vascular smooth muscle relaxation, which in turn leads to increased blood flow, heat and redness of the skin

– Production of pro-inflammatory cytokines

– Increased permeability of blood vessels, which translates into swelling via increased migration of fluid, proteins, and white blood cells

– Disruption of skin barrier function by inhibiting the cornification process

plantain Inhibition of nitric oxide production accelerates skin barrier repair after injury

• Stratum corneum (SC) is a key element of the selectively permeable and protective barrier function of the skin

• SC is made of terminally differentiated epidermal keratinocytes composed of specific proteins crosslinked by the action of transglutaminases

• NO production has been shown to alter SC formation both directly and indirectly (1) (2)

• Application of inhibitor of nitric oxide production LNAME on the skin of hairless mice accelerated the recovery of the skin barrier after tape stripping

                                                                                             

As nitric oxide has been shown to be an upstream mediator of both skin barrier dysfunction as well as inflammation, an inhibitor of NO could be expected to provide therapeutic benefit to atopic dermatitis patients 

plantainNO neutralization is effective in treating atopic dermatitis

• Pharmacological inhibition of nitric oxide may be achieved via inhibition of nitric oxide synthase, inhibition of downstream mediators and nitric oxide inhibition or scavenging

• Several studies have shown that the use of NO inhibitors was effective in reducing AD symptoms in humans :

– Intradermal injections of NO synthase inhibitor LNAME reduced erythema in lesional skin of psoriasis and atopic dermatitis patients (1)

– The NO synthase inhibitor NLA was effective in reducing lesions and pruritus in atopic dermatitis patients (2)

– Atopic dermatitis patients treated with NO scavenger Vitamin B12 cream continuously improved during the treatment period(3)

plantainthe medicinal uses of Plantago lanceolata have been known for centuries

• P. Lanceolata (ribwort plantain) is a common perennial weed that is recognized by the European Medicines Agency as a medicinal plant

• Traditional uses recognized by the EMA are the symptomatic treatment of oral and pharyngeal irritations and the treatment of dry cough

• Other traditional uses include treatment of inflammation or irritation of the skin

• Herbal preparations include both oral and topical forms

• ALTHEYS French Laboratory is the first company to isolate and patent the active molecules of P. lanceolata

plantainextracts of Plantago show anti-inflammatory activity in vitro and in vivo

• Plantago lanceolata extracts inhibited NO production and iNOS mRNA expression in LPS/IFNγ-stimulated murine macrophages in a concentration-dependent manner in vitro (1)

• (Bottom graph) Plantago extracts showed significant anti-inflammatory activity in the modified hen’s egg chorioallantoic membrane test (HET-CAM) (2)

• Plantago extracts significantly inhibited paw edema in rats induced by carrageenan (3)

• (Bottom left graph) Oral administration of aqueous extracts (AE) of Plantago significantly reduced chronic inflammation induced by croton oil on the air pouch of rats. Indomethacin was used as positive control. 5 animals per group

plantainAltheys French Laboratory is the first to isolate the active molecules in Plantago lanceolata extracts to fight eczema and dermatitis

                                

plantaino-quinone, isolated from P. lanceolata, is significantly more potent than other known NO scavengers

plantainintellectual property of Altheys

• Altheys French Laboratory has filed patent applications in Europe in 2015 on the use of o-quinone extracted from Plantago Lanceolata for the treatment of atopic dermatitis and other medical conditions (including arthritis, psoriasis, bronchitis, sepsis, etc.)

• Patent applications claim molecules (o-quinones), processes for preparing extracts containing these molecules, and their uses in the treatment of several dermatological and non-dermatological diseases in topical and non-topical formulations

• The patented process for preparing Plantago lanceolata extracts is a proprietary method to enrich the extracts in o-quinone and other active molecules

                                                             

plantainAltheys French Laboratory Atopic Skin Care Positioning

• 80% of atopic dermatitis patients have a mild to moderate form of the disease.

• For these patients, regular use of emollients with occasional use of corticosteroids or calcineurin inhibitors is sufficient to control the disease

• However, many patients are reluctant to use corticosteroids (“steroid anxiety”) and calcineurin inhibitors – Corticosteroids are not recommended for long-term use, over a large body surface, or on the face – Calcineurin inhibitors carry a black box warning for T-cell lymphoma

• Altheys French Laboratory Skin Care combines a high quality emollient with potent natural nitric oxide scavengers

– Safety profile supports daily use

– Anti-inflammatory which may reduce the need for steroids

– Actively promotes the repair of the skin barrier function

plantaintolerability studies conducted to support regulatory approval

plantaina post-approval clinical study is ongoing

plantainAltheys French Laboratory outperfoms Physiogel based on published trial data

                                                           

plantainAltheys French Laboratory Atopic Skin Care is a unique commercial opportunity

• Altheys French Laboratory Atopic Skin Care line of products contain emollients as well as natural botanical extracts from Plantago lanceolata enriched for potent nitric oxide scavengers

• These skin care products have antiflammatory properties and accelerate the repair of the skin barrier function

• Altheys French Laboratory products can be positioned for daily use in mild to moderate atopic dermatitis in order to improve skin barrier function and reduce the usage of corticosteroids

• Clinical studies have confirmed the safety and efficacy of Altheys French Laboratory Atopic Skin Care

• Altheys French Laboratory Atopic Skin Care has been approved as a Class IIa medical device in Europe

• Manufacturing process has been optimized with low cost of goods

• Ongoing market research study in 100 pilot pharmacies in France with over 3000 patients treated